Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders
申请人:Rafferty Michael
公开号:US20090111813A1
公开(公告)日:2009-04-30
The present embodiments are related to the compound of Formula 1 or Formula 2 below and pharmaceutical formulations thereof as well as treatments for a wide variety of Central Nervous System disorders with the pharmaceutical formulations. Some embodiments include the use of a variety of the instant compounds which surprisingly and advantageously exhibit improved pharmacokinetic and therapeutic profiles in comparison to pivagabine.
The effect of substitution on the utility of piperidines and octahydroindoles for reversible hydrogen storage
作者:Yi Cui、Samantha Kwok、Andrew Bucholtz、Boyd Davis、Ralph A. Whitney、Philip G. Jessop
DOI:10.1039/b718209k
日期:——
Substituted piperidines and octahydroindoles are compared in terms of their usability as reversible organic hydrogen storage liquids for hydrogen-powered fuel cells. Theoretical Gaussian calculations indicate which structural features are likely to lower the enthalpy of dehydrogenation. Experimental results show that attaching electron donating or conjugated substituents to the piperidine ring greatly increases the rate of catalytic dehydrogenation, with the greatest rates being observed with 4-aminopiperidine and piperidine-4-carboxamide. Undesired side reactions were observed with some compounds such as alkyl transfer reactions during the dehydrogenation of 4-dimethylaminopiperidine, C–O and C–N cleavage reactions during hydrogenation and/or subsequent dehydrogenation of 4-alkoxy and 4-amino indoles, and disproportionation during the hydrogenation of 4-aminopyridine.